

Welcome

COSD Roadshow 2018

Taunton 28th February 2018



Introduction

• Andrew Murphy (Head

Your Local National Cal

- Fire Alarms & Fire Exits
- Toilets
- Telephones Please ca
- Delegate Packs
- 5 minutes to introduce of
- Agenda for Today

09:30	Reception, Coffee and Registration
10:00	Start Morning Session - COSD
	What's in COSD v8.0 (Q+A) – Andrew Murphy
10:50	Comfort Break
11:00	Round table discussion
	What works, what doesn't, future changes (Additions,
44.20	Deletions + why)
11:30 11:45	Open discussion on suggestions from round table work The New CancerStats2 Reporting Portal
12:10	National Cancer Audit Presentation (to be agreed)
12.10	National Cancer Audit Presentation (to be agreed)
12:30	Lunch + Networking
13:15	Start Afternoon Session - CWT
	The new CWT system
	System changes (incl. system demo)
	How to access data in the new system and reporting
	functionality (iView+)
	What is the National Cancer Waiting Times Monitoring Data
	Set v2.0?
	Dataset changes and additions
	Inter-Provider Transfers and breach allocation
	The 28 day Faster Diagnosis Standard
	What is the new Standard?
	Faster Diagnosis Standard items
11.15	Implementation plan to 2020
14:15 <i>14:4</i> 5	Panel Q&A (with presenters of above sessions) Comfort Break
15:00	Round table discussion
13.00	What works, what doesn't, future changes (Additions,
	Deletions + why)
15:30	Open discussion on suggestions from round table work
15:45	Finish



COSD

The Importance of Working Together

Andrew Murphy Head of Cancer Datasets

National Cancer Registration and Analysis Service (NCRAS) Public Health England



Who are NCRAS

- NCRAS are the National Cancer Registration and Analysis Service.
- We collect data on every patient who is diagnosed with a registrable Tumour in England
 - 350,000 new cases registered each year
- We get data from COSD, Pathology, PAS, SACT, RTDS, HES, Cancer Audits and ONS (death certificates)
- This allows us to do some fantastic analysis at Trust, Regional and National level
- I'm here today to outline the changes to COSD v8, and hopefully encourage a closer working community, improving data completeness and quality



Overview - COSD


- The Cancer Outcome and Services Dataset (COSD) is the largest 'Cancer Data' collection process in England covering all tumours diagnosed and treated in secondary care.
- The Dataset has been reviewed and wherever possible the agenda set by all the National 'Site Specific Clinical Reference Groups' (SSCRG's), National Cancer Intelligence Experts and the COSD Advisory Board (which includes Trust representation).
- The dataset has a CORE and Pathology section, which requires data to be collected on every patient and then 13 site specific tumour groups, which require data on specific tumours (but not on every patient).
- Certain data are monitored to improve data quality and completeness



Clinical Support Essential

- MDT/Pathway Coordinator and Cancer Services provide a huge support to all the MDT's and submit data (collected in real-time) to the NCRAS
- Some data needs Clinical Support, via the MDT and clinical teams (including the Nurse Specialists)
- Ideally live data collection at the MDT is the best process, but we know this
 is not always possible. Therefore discussions and decisions made at MDT
 need to be clear and easy for data collection
- Cross dataset collaboration is required (including National Audits), to prevent duplication of data collection. Most Trusts use the same systems to collect data (Somerset/Infoflex) and then report these separately – Collect it once but report these across many datasets (COSD/Audits/CWT)







Challenge Your Data

- It is important that each MDT reviews their data submitted by the Trust to NCRAS, and having a clinical champion provides strong local leadership.
- Using the portal provides greater support and has already been adopted by other Audits?
- You can view:
 - Incidence, Survival and Mortality data (at population level)
 - COSD (at Trust, Tumour and element level)
 - NLCA (Lung)
 - NPCA (Prostate)
- Coming soon is 'CancerStats2'
 - and we have a presentation later this morning to demonstrate the amazing power of this new reporting portal.



Next Phase

- COSD v8 has been reviewed for a launch in April 2018
- Careful consideration has been taken around removing any duplicated data item(s) throughout the dataset, or adding new data-item(s) that are required to support clinical audit dataset(s)
 - Examples here are:
 - pathology, where a data item has been removed from the Royal College of Pathologists (RC Path) core datasets, at Tumour level
 - where new data items are required to support e.g. National Lung Cancer Audit (NLCA) and National Prostate Cancer Audit (NPCA)
 - where staging or other fields are now outdated and require updating
- All these changes are required to ensure that COSD continues to be clinically accurate and relevant.



Building on the work started in v7.0

- Extensive consultation was conducted over a 6 month period with 47 key groups or clinical experts including:
 - all the Site Specific Clinical Reference Groups (SSCRGs)
 - experts from within the National Cancer Registration and Analysis Service (NCRAS)
 - as well as Clinical Support and Advice from the chair of the Royal College of Pathologists Working Group on Cancer Services.
 - for the first time, cancer charities and patient groups were also consulted upon.
- This process completes the work started in 2016 and allowed the data set to be clinically reviewed, validated and updated by experts in all fields of cancer and provide a clinically sound set of data to be collected from 2018 onwards.
- This also meets crucial recommendations in the Achieving World-Class Cancer Outcomes, A Strategy for England 2015-2020 (Cancer Taskforce Report).



COSD v8.0 Timeline

- Full stage submission = September 2017 DCB meeting acceptance
- ISN publication = 28th September 2017
- Implementation period = 28 Sept 2017 to 31 March 2017 = 6 months
- Start of new Data Collection 1 April 2018
- Full Conformance (to allow rollout) = from 1 July 2018



Exciting New Additions

- New pathway to record 'Non-Primary Cancer Pathway':
 - new data items for Recurrences, Progression and Transformation
 - improved ability to record all metastatic sites
- New 'Person Sexual Orientation Code (at diagnosis)' field
- Improved 'Nurse Specialist' sections:
 - including 'Risk Factors'
 - 'Holistic Needs Assessment' becomes Required for all patients
- Improved 'Clinical Trials' section
- Improved 'Staging' section to allow for:
 - both UICC & AJCC TNM staging
 - ability to record the Trust which staged the patient



COSD

The changes

Andrew Murphy Head of Cancer Datasets

National Cancer Registration Service (NCRS) Public Health England



Quick Overview...

- 39 new data items have been added most of these data are either collected already in cancer management systems or within the Multi-Disciplinary Team meeting (MDTm) and have been heavily consulted upon with the Site Specific Clinical Reference Groups. Of which:
 - 1 data item has been added, which complies with the Information Standard SCCI2094 on sexual orientation.
 - 13 data items have been added, to create a new section for the accurate collection of data for Liver tumours.
 - 3 data items have been added, to create a new section for the accurate collection of risk factors.
 - 1 data item has been added, which complies with the Information Standard SCCI0034 on SNOMED CT diagnosis.
- 92 data items have been deleted of which 18 were to remove duplication within the data set, whilst 48 were to remove linked data collected in other national data sets. Of which:
 - 6 Pathology data items have been deleted to reduce duplication or to align with revisions to Royal College of Pathologists (RC Path) core data sets.



Quick Overview (continued)...

- 57 data items have been re-aligned or moved within the data set. This ensures that data nests correctly within the XML and will help with data collection, quality and ascertainment.
- 51 data items have been amended for better synchronisation across the NHS
 Data Model and Dictionary, to allow for changes in new staging systems and/or
 for clarification of descriptions and should improve the collection of the
 standard. Of which:
 - 11 data items have been updated to meet the new requirement due to the new Health and Social Care Organisation Reference Data standard (ANANA) -SCCI0090.
- Implementation will be between 29/09/2017 and 31/03/2018 (6 months).
- Data collection will start from 01/04/2018 (with a three month roll-out period between 01/04/2018 and 30/06/2018).
- Full conformance from 01/07/2018 (reported in the July batch within the September upload).



So What Does That Mean?

- I am now going to go through the dataset, outlining the changes in more detail.
- This afternoon, my colleagues from Cancer Waits will talk to you all about their changes and how they will affect you too.
- Extensive work have been continuing behind the scenes with system suppliers and Information Departments, to provide more support where needed to ensure the transition is a pain free as possible.
- A full set of documentation is available to help and support you with this including:
 - User Guides
 - Datasets (in excel format)
 - Xml schemas (with examples and change logs) to support development



Main changes in 'CORE'

- The first big change for v8 is around the addition of a new 'Non-Primary Cancer Pathway'
 - to achieve this the old Date of Recurrence was removed and replaced with

CR6500	CORE - DIAGNOSTIC DETAILS	DATE OF NON PRIMARY CANCER DIAGNOSIS (CLINICALLY AGREED)*	*For linkage purposes DATE OF PRIMARY DIAGNOSIS (CLINICALLY AGREED) or DATE OF NON PRIMARY CANCER DIAGNOSIS (CLINICALLY AGREED) is required as mandatory. Record the date where the non primary cancer diagnosis was confirmed or agreed (This will normally be the date of the authorised pathology report which confirms this or if this is not available at the time it will be the date of the Multidisciplinary Team Meeting when the diagnosis was agreed)	
--------	------------------------------	--	---	--

 this then allows to you specify what type of Non-Primary Cancer Pathway the patient is on, as agreed by the MDT by using the following field:

	CORE - NON PRIMARY		Indicate what pathway the patient is on if this is not		01	Recurrence
CR6510	CANCER PATHWAY	NON PRIMARY CANCER PATHWAY	the Primary Cancer Pathway	an2	02	Progression
	ROUTE				03	Transformation



Main changes in 'CORE' (Continued)...

 If you select Recurrence, you can then specify what type of recurrence or metastatic disease

	CORE - NON PRIMARY CR6520 CANCER PATHWAY ROUTE				01	Local
CR6520		RECURRENCE OR METASTATIC TYPE	ECURRENCE OR METASTATIC Indicate the type of recurrence or metastatic disease diagnosed by the clinical team	an2	02	Regional
					03	Distant

Finally you can also record the location of the metastatic spread

	Start of repeating item - Me Multiple occurrences of this					
					02	Brain
					03	Liver
					04	Lung
					06	Multiple metastatic sites
	CORE - NON PRIMARY	METASTATIC SITE	The site of the metastatic disease, if any	an2	07	Unknown metastatic site
CR1590	CANCER PATHWAY		The site of the metastatic disease, if any		08	Skin
CK 1590	ROUTE	METASTATIC SITE	More than one site can be recorded		09	Distant lymph nodes
	ROUTE		More than one site can be recorded		10	Bone (excluding Bone Marrow)
					11	Bone marrow
					12	Regional lymph nodes
					98	Other metastatic site
					99	Other metastatic site
	End of repeating item - Meta	astatic Site				

and you can record more than one



Main changes in 'CORE' (Continued)...

 Some of you would have also noticed the ability to record both Transformation and Progression within this section.

	CORE - NON PRIMARY	NON PRIMARY CANCER PATHWAY	Indicate what pathway the patient is on if this is not	an2	01	Recurrence
CR6510	CANCER PATHWAY		MARY CANCER PATHWAY the Primary Cancer Pathway		02	Progression
	ROUTE				03	Transformation

- This allows a Trust to record these data correctly, where they know the
 patients diagnosis is <u>NOT</u> a new diagnosis of cancer, but instead a
 progression or transformation of an existing disease...
 - and where the Trust has no record of the previous disease.
- Now you can record a new record as a Non-Primary Cancer Diagnosis, and for progression you can also add the new ICD code following the progression using:

CR6900	CORE - NON PRIMARY CANCER PATHWAY ROUTE	PROGRESSION (ICD)	Where a cancer has progressed, record the ICD10 code of the original diagnosis. This will normally be agreed at the MDT by the clinical team.
--------	---	-------------------	--



Progression/Transformation changes (at Diagnosis)...

 However, if you already have a record of cancer on your local system, you can also now add any metastatic spread (at diagnosis), as well as the progression and/or transformation details to the original record as follows:

CR6960	CORE - DIAGNOSIS	METASTATIC TYPE	In	ndicate the type of metastatic disease diagnosed by the clinical team			01 02 03	Local Regional Distant
	Start of repeating item	- Metastatic Site						
	Multiple occurrences of	this item are permitted						
							02	Brain
							03	Liver
							04	Lung
							06	Multiple metastatic sites
				he site of the metastatic disease, if any, at diagnosis.			07	Unknown metastatic site
CR6970	CORE - DIAGNOSIS	METASTATIC SITE				an2	08	Skin
CK6970	CORE - DIAGNOSIS	WETASTATIC SITE				anz	09	Distant lymph nodes
				More than one site can be record	ded		10	Bone (excluding Bone Marrow)
							11	Bone marrow
							12	Regional lymph nodes
							98	Other metastatic site
							99	Other metastatic site
	End of repeating item -	Metastatic Site						

you can add the Date of the progression

	Start of repeating item - Progression									
CR6910	CORE - DIAGNOSIS	PROGRESSION DATE (PRIMARY PATHWAY)	The DATE the progression was agreed by the clinical team.	an10 ccyy-mm- dd						
	End of repeating item - I	Progression								



Transformation changes (at Diagnosis)...

 Using the following fields allows to you to accurately record the transformation...

	Start of repeating item - Transformation						
			The version of SNOMED used to encode MORPHOLOGY (SNOMED) PATHOLOGY and		01 02	SNOMED II SNOMED 3	
		SNOMED VERSION	TOPOGRAPHY (SNOMED) PATHOLOGY		03	SNOMED 3.5	
CR7030	CORE - DIAGNOSIS	(TRANSFORMATION)	Versions of SNOMED prior to SNOMED CT ceased to be licenced by The International	an2	04	SNOMED RT	
			Health Terminology Standards Development Organisation (IHTSDO) after April 2017 other		05	SNOMED CT	
			than for historical content		99	Not Known	
CR7000	CORE - DIAGNOSIS	MORPHOLOGY (SNOMED) TRANSFORMATION	This is the TRANSFORMATION DIAGNOSIS using the SNOMED International / SNOMED CT code for the cell type of the tumour recorded as part of a Cancer Care Spell. This can be recorded as well as or instead of MORPHOLOGY (ICD03) TRANSFORMATION. Versions of SNOMED prior to SNOMED CT ceased to be licenced by The International Health Terminology Standards Development Organisation (IHTSDO) after April 2017 other than for historical content	min an6 max an18			
CR7010	CORE - DIAGNOSIS	MORPHOLOGY (ICDO3)* TRANSFORMATION	The morphology code for the transformation of the cancer as defined by ICD-O-3. This can be recorded as well as or instead of MORPHOLOGY (SNOMED) TRANSFORMATION.	min an5 max an7			
CR7020	CORE - DIAGNOSIS	TRANSFORMATION DATE (PRIMARY PATHWAY)	The DATE the transformation was agreed by the clinical team.	an10 ccyy-mm- dd			
	End of repeating item - 1	Fransformation					

We would expect a date within this section for each submission



Changes to Nurse Specialist 'CORE' data

 'Clinical Nurse Specialist Indication Code' has been improved to include a new attribute... Yes - Clinical Nurse Specialist not present when PATIENT given diagnosis but the patient was seen by a trained member of the Clinical Nurse Specialist team

 These have also been moved into a new group called 'Core - Clinical Nurse Specialist + Risk Factor Assessment'

this has allowed additional 'NEW' data to be added around 'Smoking

Status'...

			1	Current smoker							
	Specify the current smoking status of the patient.									2	Ex smoker
			3	Non-smoker - history unknown							
SMOKING STATUS		an1	4	Never smoked							
			Not Stated (PERSON	Not Stated (PERSON asked but							
							4	declined to provide a response)			
			9	Unknown							

Y5

and 'History of Alcohol' (Current and Past)...

	Specify the current history of alcohol consumption for		1	Heavy (>14 Units per week)
	the patient (≤3 months) from date of diagnosis		2	Light (≤14 Units per week)
HISTORY OF ALCOHOL (CURRENT)	, , ,	an1	3	None in this period
HISTORY OF ALCOHOL (CURRENT)	These are based on the UK Chief Medical Officers'	anı	7	Not Stated (PERSON asked but
	Alcohol Guideline Review (Jan 2016)			declined to provide a response)
	Alcohol Guideline Review (Jan 2010)		9	Not Known (Not recorded)
	Specify the past history of alcohol consumption for		1	Heavy (>14 Units per week)
	the patient (>3 months) from date of diagnosis	an1	2	Light (≤14 Units per week)
HISTORY OF ALCOHOL (PAST)	the patient (>5 months) from date of diagnosis		3	None ever
THOTOKY OF ALCOHOL (FAST)	These are based on the UK Chief Medical Officers'	aill	7	Not Stated (PERSON asked but
	Alcohol Guideline Review (Jan 2016)			declined to provide a response)
	Alcohol Guideline Review (Jan 2010)		9	Not Known (Not recorded)



Other changes to CORE...

- There are other changes within the CORE, where we have:
 - Improved the whole Clinical Trials pathway
 - adding dates when the patient agreed to the trail and when it started
 - Updated the Staging fields
 - allowing for both AJCC and UICC to be recorded as applicable
 - adding a new field to record the Trust/Organisation who did the staging
 - both at Pre-Treatment and Integrated Stage

adding new fields to record both the Edition and the Version number of the staging system used

Added an Adjunctive Therapy Indicator...

This compliments the updated Treatment Intent...

1	01	Curative
	02	Palliative
	03	Disease Modification *
		Diagnostic * *
	05	Staging * *
	08	Other
	09	Not Known



Site Specific Datasets Changes...

- You will notice across the dataset that **CTYA** items may have moved, either:
 - to the CORE, because on clinical advice we believe that these can be collected on more than just CTYA patients or
 - within their site specific parent (Sarcoma to Sarcoma) etc.
- Breast has a new item for recording the 'Menopausal Status'
- Gynaecological has an updated 'Consultant Grade'
- Haematological has an updated 'FLIPI 2 Index Score'
- Head and Neck has a new 'Speech and Language Therapist' date field
- There is a whole new section for 'Liver'
- Lung has had two fields extend their format to allow for accurate data recording
- Urological has got three new fields aligning them to the NPCA submissions



COSD - CORE Pathology

- Core pathology has had the least changes and continues to have its own dataset and schema.
- We will also investigate to see if it is possible within v9 to completely separate COSD Pathology from COSD Patient Pathway.
- Work is ongoing with the major pathology suppliers to have compliant LIMS available for Trusts to implement or upgrade to.
- The COSD Governance Board is aware of the delay, and difficulties in the transition to COSD xml reporting for pathology
- There are great benefits from reporting using COSD xml for pathology
 - reduced transcription errors
 - faster reporting of pathological outcomes (28 day targets)
 - ability to map to multiple datasets of accurate recording (interoperability)



COSD - CORE Pathology (Continued)...

- There are only 13 changes to this dataset, of which 6 of these are deletions
 - these are primarily where we have grouped all pathology grade into one field 'Grade Of Differentiation (Pathological)' (except colorectal)
- 'Service report Identifier' and 'Pathology Observation Report Identifier' have extended field lengths
- There are updated Staging fields to allow for:
 - both AJCC and UICC to be recorded as applicable
 - new fields to record both the 'Edition' and the 'Version Number' of the staging system used
- Colorectal pathology changes include:
 - an update to 'Response To Preoperative Therapy'
 - a new field for 'Grade Of Differentiation (Colorectal Pathological)'
- 'Sarcoma Surgical Margin Adequacy' moved into Sarcoma pathology



Finally...

- Although there were less changes this year, the challenges were equally as difficult and complex
- We now have a more balanced dataset, which better reflects current clinical practice, and allows for the accurate recording of recurrences, progression, transformation and the changes to the TNM staging systems from Jan 2018
- Our next challenge is to improve the completeness and ascertainment of data collected at Trust level
 - using CancerStats2 later this year will help you with this
- Again like last year, this is your challenge:
 - your opportunity to support the MDT and National Analysts
 - to improve data collection, accuracy and quality of data recorded
 - ultimately this whole process will improve the treatment pathways for patients



Any Questions?



Group Discussion

COSD - What works, what doesn't and future changes (Additions, Deletions and why)?



Group Discussion...

- 30 Minutes
- Is the dataset too big?
- What data are really difficult to collect and why?
 - laboratory results, CTYA, Haematology, other data or processes
- Should the dataset be reduced in size?
 - If so, what should we remove and why?
- What new things would you like to see in COSD in the future? Think about:
 - who is going to collect these?
 - how easy they are to collect?
 - what are they going to be used for?
- The next COSD change will be in 2020, so this is your chance to influence this change. "Your opinions really matter"